AU3572895A - Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase - Google Patents

Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase

Info

Publication number
AU3572895A
AU3572895A AU35728/95A AU3572895A AU3572895A AU 3572895 A AU3572895 A AU 3572895A AU 35728/95 A AU35728/95 A AU 35728/95A AU 3572895 A AU3572895 A AU 3572895A AU 3572895 A AU3572895 A AU 3572895A
Authority
AU
Australia
Prior art keywords
pla2
compound
sequence homology
associated phospholipase
lipoprotein associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35728/95A
Inventor
Simon Quentyn John Rice
Christopher Donald Southan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU3572895A publication Critical patent/AU3572895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU35728/95A 1995-09-29 1995-09-29 Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase Abandoned AU3572895A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1995/002320 WO1997012984A1 (en) 1995-09-29 1995-09-29 COMPOUND HAVING SEQUENCE HOMOLOGY WITH LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 (Lp-PLA2)/PAF ACETYL HYDROLASE

Publications (1)

Publication Number Publication Date
AU3572895A true AU3572895A (en) 1997-04-28

Family

ID=10769182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35728/95A Abandoned AU3572895A (en) 1995-09-29 1995-09-29 Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase

Country Status (4)

Country Link
EP (1) EP0853673A1 (en)
JP (1) JPH11514228A (en)
AU (1) AU3572895A (en)
WO (1) WO1997012984A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (en) 1993-06-25 2000-09-07 Smithkline Beecham Plc PHOSPHOLIPASE A2 TIED TO LIPOPROTEIN, INHIBITORS THEREOF AND THEIR USE FOR DIAGNOSIS AND THERAPY
JPH1017600A (en) * 1996-06-28 1998-01-20 Suntory Ltd Blood platelet activating factor acetyl hydrolase and its gene
CA2267994C (en) * 1997-08-13 2005-04-12 Icos Corporation Truncated platelet-activating factor acetylhydrolase
CN106957824B (en) * 2016-12-27 2018-02-23 南京诺唯赞医疗科技有限公司 The monoclonal antibody of the anti-human Lp PLA2 albumen of resistance to lipoprotein interference and its application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (en) * 1993-06-25 2000-09-07 Smithkline Beecham Plc PHOSPHOLIPASE A2 TIED TO LIPOPROTEIN, INHIBITORS THEREOF AND THEIR USE FOR DIAGNOSIS AND THERAPY
DE69427392T2 (en) * 1993-10-06 2002-05-23 Icos Corp ACETHYL HYDROLASE OF THE PLATE ACTIVATING FACTOR

Also Published As

Publication number Publication date
WO1997012984A1 (en) 1997-04-10
JPH11514228A (en) 1999-12-07
EP0853673A1 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
AU697808B2 (en) Fibers having phosphorus-containing coatings
EP0712148A3 (en) Plasma display system
AU4140596A (en) Improved mechanical connector for securing compatible medcal instruments together
AU5022396A (en) An acoustic transmisson system
AU7374696A (en) Gasket system for emi isolation
AU6849896A (en) Universal mount for rifle
AU5375696A (en) Inspection of optical components
AU2796497A (en) Angled opto-mechanical connector
AU4409997A (en) Optical fourier processing
EP0749026A3 (en) An optical fiber connector
AU6236298A (en) Flexfoils having connector tabs
AU7183196A (en) Optical connector
AU694850B2 (en) Multi-downcomer high performance tray assembly
EP0740371A3 (en) Snap-fit connector
AU1200397A (en) Signatures of marine seismic sources
AU6339396A (en) Gasket layer identifiers
AU3151495A (en) Lipoprotein cholesterol assays
AU1038797A (en) Autostereoscopic display
AU3572895A (en) Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase
AU5284496A (en) S-adenosyl-L-homocystein hydrolase promoter
AU4576896A (en) Optical connector
AU6312496A (en) Mechanical connectors
AUPM943194A0 (en) Viewing assembly
AUPO852397A0 (en) Stereoscopic viewing system
AUPN675195A0 (en) Malathion carboxylesterase